Crossmark

Primary tumour response on breast MRI as a predictor of axillary pathologic response in breast cancer patients treated with neoadjuvant chemotherapy

Crossref DOI link: https://doi.org/10.1007/s00330-025-12249-x

Published Online: 2025-12-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

van Amstel, Florien J. G. https://orcid.org/0009-0007-9874-8007
van Mierlo, Rik G. M.

Nelemans, Patty J.

Engelen, Sanne M. E.

Houwers, Janneke

Kooreman, Loes F. S.

Tjan-Heijnen, Vivianne C. G.

Siesling, Sabine

Smidt, Marjolein L.

van Nijnatten, Thiemo J. A.
Funding

Funding for this research was provided by:

KWF Kankerbestrijding (14055)

KWF Kankerbestrijding
License Information

Text and Data Mining valid from 2025-12-23

Version of Record valid from 2025-12-23
More Information

Article History

Received: 8 July 2025

Revised: 4 November 2025

Accepted: 24 November 2025

First Online: 23 December 2025

Compliance with ethical standards

:

: The scientific guarantor of this publication is Thiemo J.A. van Nijnatten, Radiology and Nuclear Medicine, Maastricht University Medical Centre+, Maastricht, the Netherlands.

: Prof. Dr. Marjolein L. Smidt received institutional research funding not related to this study from Servier, Pharma, Nutricia and Illumina for the microbiota study. Dr. Thiemo J.A. van Nijnatten received speaker honoraria and institutional grant support and reports participation in medical advisory board meetings for Bayer and GE Healthcare, not related to the content of this study. Dr. Thiemo J.A. van Nijnatten reports participation in medical advisory board meetings for Screenpoint Medical, not related to the content of this study. Dr. Loes F.S. Kooreman received institutional honoraria for education and national guideline advisory. Prof. Dr. Vivianne C.G. Tjan-Heijnen received institutional research funding outside this work, from Novartis, E Lilly, Daiichi Sankyo, AstraZeneca and Gilead, and received honoraria from Novartis and E Lilly. Prof. Dr. Sabine Siesling is a member of the advisory board of Evidencio and Vivica, not related to this study. The other authors have no conflicts of interest to declare that are relevant to the content of this article.

: One of the authors (P.J. Nelemans) has significant statistical expertise. No complex statistical methods were necessary for this paper.

: Written informed consent was waived by the Institutional Review Board.

: Institutional Review Board approval was obtained by the Medical Ethics Review Committee azM/UM (reference number: 2022-3481) of Maastricht University Medical Centre+, Maastricht, the Netherlands.

: No study subjects or cohorts have been previously reported.

:

Document is current

Any future updates will be listed below